“…The authors have long been engaged in the study of various types of heterocycles [ 3 , [15] , [16] , [17] , [18] , [19] ], primarily as anti-infective and anti-cancer agents with the aim of obtaining substances with dual (anti-cancer + antibacterial) activity [ [20] , [21] , [22] , [23] , [24] , [25] , [26] ], because such therapeutics are particularly advantageous in the treatment of oncological patients who have drug-suppressed immunity and for whom even banal infections and opportunistic pathogens are a threat. So impressed with the global interest in quinazolin-4(3 H )-ones as antibacterial compounds [ 4 , [27] , [28] , [29] , [30] , [31] ], the previously described anticancer 2,3-disubstituted-quinazolin-4(3 H )-one derived Schiff bases [ 32 , 33 ] were screened for their antimicrobial activity, and their cytotoxic potential was tested against the human monocytic leukemia cell line THP-1 and thus the spectrum of cytotoxic activities published earlier [ 32 , 33 ] was extended to another line.…”